Alethia Young Biography and Net Worth

Chief Financial Officer, Bicycle Therapeutics of PTC Therapeutics

Ms. Young has served as a member of our Board since 2022. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing and has served as the Chief Financial Officer of Bicycle Therapeutics PLC, a Nasdaq-listed biopharmaceutical company since June 2023. From April 2022 to June 2023, Ms. Young served as Chief Financial Officer of Graphite Bio, Inc., a Nasdaq listed biopharmaceutical company. From 2018 to March 2022, Ms. Young served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse from August 2015 to August 2018 and Deutsche Bank from July 2011 to July 2015. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions. Ms. Young served on the board of directors for BUILD NYC from 2021 to 2023. Ms. Young has also served as a member of the board of directors of Pacira BioSciences, Inc., a Nasdaq-listed biopharmaceutical company, since October 2023. She earned a B.A. in Economics and Spanish from Duke University.

What is Alethia Young's net worth?: The estimated net worth of Alethia Young is at least $368,664.22 as of September 6th, 2023. Ms. Young owns 9,067 shares of PTC Therapeutics stock worth more than $368,664 as of October 31st. This net worth evaluation does not reflect any other assets that Ms. Young may own. Learn More about Alethia Young's net worth.
How do I contact Alethia Young?: The corporate mailing address for Ms. Young and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Alethia Young's contact information.
Has Alethia Young been buying or selling shares of PTC Therapeutics?: Alethia Young has not been actively trading shares of PTC Therapeutics during the past quarter. Most recently, Alethia Young sold 11,666 shares of the business's stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $39.86, for a transaction totalling $465,006.76. Following the completion of the sale, the director now directly owns 9,067 shares of the company's stock, valued at $361,410.62. Learn More on Alethia Young's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 7/16/2024.

Alethia Young Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/6/2023	Sell	11,666	$39.86	$465,006.76	9,067

Alethia Young Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $39.92

$39.70

$41.07

50 Day Range

MA: $36.45

$31.42

$42.50

2 Week Range

Now: $39.92

$17.53

$43.40

Volume

458,584 shs

Average Volume

851,311 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.